Rationale and study design for the first precision medicine randomized placebo-controlled trial in the 16p11.2 deletion syndrome.

This is the first major clinical trial testing a medication called arbaclofen for children with 16p11.2 deletion syndrome, a genetic condition that affects speech and movement. The study will compare the medication to a placebo (dummy pill) in 60 children aged 5-17 years. Researchers want to see if arbaclofen can help improve speech problems, which are common in this syndrome. This is important because there are currently no proven medications for this genetic condition.

L16hthouse is the first randomized placebo-controlled trial investigating arbaclofen treatment in 60 youth (ages 5-17) with 16p11.2 deletion syndrome. This multi-site phase 2 trial evaluates whether arbaclofen, a GABA-B receptor agonist that showed promise in mouse models and previous autism trials, can improve speech articulation (primary outcome) and motor/cognitive functions (secondary outcomes). The study represents a precision medicine approach for this specific genetic syndrome, which commonly involves speech, language, and motor coordination difficulties. The trial incorporates novel computer-based assessments alongside standardized clinical measures, potentially advancing outcome measurement methodology for rare genetic conditions affecting neurodevelopment.

Represents important advancement in precision medicine for rare genetic syndromes. If successful, could establish first evidence-based pharmacological treatment for 16p11.2 deletion syndrome speech difficulties. The novel outcome measures may benefit future clinical trials in similar rare conditions, advancing research methodology for genetic neurodevelopmental disorders.

This is a study design paper reporting trial methodology rather than results. The actual safety, efficacy, and tolerability data are not yet available. Generalizability may be limited by the rarity of 16p11.2 deletion syndrome and specific age range studied.

Chromosome 16p11.2 deletion syndrome is a genetic syndrome that includes difficulties in speech, language, and motor coordination. Arbaclofen, a selective GABA-B receptor agonist, has improved motor functioning and memory in mouse models. Prior clinical trials of arbaclofen in fragile X syndrome and autism spectrum disorder suggested benefit for social communication. L16hthouse (NCT04271332) is a multi-site, double-blind, randomized, placebo-controlled phase 2 trial to evaluate safety, efficacy, and tolerability of arbaclofen compared in 60 youths with 16p11.2 deletion syndrome (5 to 17:11 years) randomized on a 1:1 ratio.

Primary outcomes included speech articulation, measured by the Goldman Fristoe Test of Articulation 3 (GFTA-3). Secondary outcomes included objective dysarthria indices, memory, motor control, and cognitive function, assessed with both standardized clinical measures and novel, computer-based assessments with automated scoring. Exploratory outcomes included attention, autism traits, and electrophysiological responses. L16hthouse is the first randomized trial in 16p11.2 deletion syndrome and uses an array of novel outcome measures to assess potential benefit in this population.

In addition to providing potential insights about the safety, efficacy, and tolerability of arbaclofen, L16hthouse will provide an initial assessment of how these developmental outcome measures perform in a clinical trial across a broad age range.NCT04271332; 2020-02-13.